CO2024006258A2 - Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos - Google Patents
Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlosInfo
- Publication number
- CO2024006258A2 CO2024006258A2 CONC2024/0006258A CO2024006258A CO2024006258A2 CO 2024006258 A2 CO2024006258 A2 CO 2024006258A2 CO 2024006258 A CO2024006258 A CO 2024006258A CO 2024006258 A2 CO2024006258 A2 CO 2024006258A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- factor
- clot formation
- domain
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270629P | 2021-10-22 | 2021-10-22 | |
| PCT/US2022/078530 WO2023070097A2 (en) | 2021-10-22 | 2022-10-21 | Factor xi a2 domain-binding antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024006258A2 true CO2024006258A2 (es) | 2024-06-27 |
Family
ID=84360943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0006258A CO2024006258A2 (es) | 2021-10-22 | 2024-05-16 | Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12304969B2 (https=) |
| EP (1) | EP4419142A2 (https=) |
| JP (1) | JP2024539157A (https=) |
| KR (1) | KR20240099304A (https=) |
| CN (1) | CN118414168A (https=) |
| AU (1) | AU2022368930A1 (https=) |
| CA (1) | CA3235457A1 (https=) |
| CL (1) | CL2024001237A1 (https=) |
| CO (1) | CO2024006258A2 (https=) |
| IL (1) | IL312308A (https=) |
| MX (1) | MX2024004849A (https=) |
| WO (1) | WO2023070097A2 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| TWI736575B (zh) * | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| CA3125303A1 (en) | 2019-01-21 | 2020-07-30 | Aronora Inc. | Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof |
-
2022
- 2022-10-21 WO PCT/US2022/078530 patent/WO2023070097A2/en not_active Ceased
- 2022-10-21 KR KR1020247016447A patent/KR20240099304A/ko active Pending
- 2022-10-21 MX MX2024004849A patent/MX2024004849A/es unknown
- 2022-10-21 US US18/048,644 patent/US12304969B2/en active Active
- 2022-10-21 EP EP22809619.4A patent/EP4419142A2/en active Pending
- 2022-10-21 CA CA3235457A patent/CA3235457A1/en active Pending
- 2022-10-21 IL IL312308A patent/IL312308A/en unknown
- 2022-10-21 CN CN202280084047.3A patent/CN118414168A/zh active Pending
- 2022-10-21 JP JP2024523663A patent/JP2024539157A/ja active Pending
- 2022-10-21 AU AU2022368930A patent/AU2022368930A1/en active Pending
-
2024
- 2024-04-19 CL CL2024001237A patent/CL2024001237A1/es unknown
- 2024-05-16 CO CONC2024/0006258A patent/CO2024006258A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4419142A2 (en) | 2024-08-28 |
| CN118414168A (zh) | 2024-07-30 |
| KR20240099304A (ko) | 2024-06-28 |
| CL2024001237A1 (es) | 2024-09-13 |
| WO2023070097A2 (en) | 2023-04-27 |
| AU2022368930A1 (en) | 2024-05-02 |
| US12304969B2 (en) | 2025-05-20 |
| US20230131338A1 (en) | 2023-04-27 |
| IL312308A (en) | 2024-06-01 |
| MX2024004849A (es) | 2024-05-06 |
| CA3235457A1 (en) | 2023-04-27 |
| WO2023070097A3 (en) | 2023-06-08 |
| JP2024539157A (ja) | 2024-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| Moro et al. | Contractile activity of the bladder urothelium/lamina propria and its regulation by nitric oxide | |
| EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
| EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
| PE20141149A1 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| MX2018008939A (es) | Anticuerpos anti-factor de la coagulacion xi. | |
| CO2021001172A2 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| MX2024012807A (es) | Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas | |
| CO2018013434A2 (es) | Anticuerpos antifactor de la coagulación xi | |
| CO6620068A2 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi) | |
| CL2021002039A1 (es) | Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522) | |
| EA202191764A1 (ru) | Замещенные оксопиридиновые производные | |
| CL2023002135A1 (es) | Proteínas de unión al antígeno complemento c3 | |
| EA201891714A1 (ru) | Галогензамещенные пиперидины в качестве модуляторов орексинового рецептора | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| CO2024017422A2 (es) | Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6) | |
| He et al. | Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR | |
| CO2024006258A2 (es) | Anticuerpos de unión al dominio a2 del factor xi y métodos para usarlos | |
| Protić et al. | Effect of wine polyphenol resveratrol on the contractions elicited electrically or by norepinephrine in the rat portal vein | |
| ECSP066925A (es) | Derivados de piperidina como antagonistas del receptor de quimiocina | |
| MX2024007732A (es) | Composiciones y metodos relacionados con el factor i del complemento. | |
| Romero-Imbachi et al. | Centruroides margaritatus scorpion complete venom exerts cardiovascular effects through alpha-1 adrenergic receptors | |
| CO2025007349A2 (es) | Anticuerpos de unión al dominio catalítico del factor xi y métodos de uso de estos |